Produce more
Radioisotopes in
a Cost-Effective way

span>New accelerator provides increased access to diagnosis solutions and enables in-house production of radiopharmaceuticals   Louvain-la-Neuve, Belgium, 26 January 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceuticals production solutions, today announces that it has launched a new low energy and compact size cyclotron, the Cyclone® KEY. The new machine will enable small and medium sized hospitals to produce their own radiopharmaceutical products in-house, whilst providing more widespread global access to diagnostic solutions in oncology, neurology and cardiology. The Cyclone® KEY was showcased on Monday 24 January 2022 during Arab Health 2022, an annual meeting in Dubai, UAE. A presentation of the new technology is available here.   Positron Emission Tomography (PET) imaging is well established for cancer diagnosis in many countries, as well as for cardiac and neurological imaging, however, there are still regions in the world with limited access to this diagnostic technology. To address these needs, IBA is making PET imaging more accessible through this new low-energy technology, comprising proton acceleration up to 9.2 megaelectron volts (MeV). The Cyclone® KEY is therefore more compact, user-friendly, cost-effective and easier to fit into existing hospital systems.   Bruno Scutnaire, Executive Vice-President of IBA's RadioPharma Solutions Division commented: “Our new cyclotron model retains all the characteristics of the Cyclone® family: productivity, reliability, and profitability, whilst providing a low energy, compact option for customers. Cyclone® KEY’s design originates from IBA’s well-established Cyclone® KIUBE, providing the highest market standards in terms of the radioisotope production capacity and reliability. We are pleased to be bringing this innovative and much needed technology to hospitals around the globe.”   The Cyclone® KEY encompasses more than 36 years of experience and innovation and has one of the smallest footprints of all clinical cyclotrons, enabling easy installation and operation. Thanks to the Cyclone® KEY’s compact size, IBA’s experts have managed to minimize the footprint of the radiopharmacy to 80m².

The clinical value of myocardial flow quantification is supported by numerous observational and clinical studies in various populations. Its use is no longer restricted to a few academic centers as the technology advances and guidelines evolves. In this webinar Dr Slomka iscussed the clinical value and practical aspects of PET quantification in cardiovascular imaging. The practical aspects and clinical value of myocardial blood flow quantification in PET in patients with cardiovascular disease By Piotr Slomka, PhD, FACC, FASNC, Director of Innovation in Imaging and Professor of medicine and cardiology, Division of Artificial Intelligence in Medicine at Cedars-Sinai. One of the most important advances in nuclear cardiology is the opportunity to quantify myocardial blood flow (MBF) and myocardial flow reserve (MFR) routinely as part of myocardial perfusion imaging (MPI) with PET. Dr Slomka will review practical aspects of the MBF measurements with PET and discuss its clinical value in the management of cardiac patients.

The Cyclone® KIUBE has been placed into its final position at HIC in Changshu, China. The new radiopharmacy will produce F-18 compounds as well as other novel radioisotopes. Congratulations to Zhijun Zhang, Gregoire Moreau and the whole team involved in this project!

After one week of rigging, the installation of the Cyclone® 70P for the Institute of Basic Science (IBS) has now started. This is the 4th installation of such system for IBA team of experts involved. Congratulations to all the people involved in this important project's milestone.